Boehringer Ingelheim

News

Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for lung cancer therapy Hernexeos.

News

Click and Boehringer Ingelheim make progress in software-enhanced drug treatment for schizophrenia with a positive phase 3 trial of their CT-155 app.

News

Bayer files its oral HER2+ lung cancer drug in China, as it extends a race to market with rival Boehringer Ingelheim.

News

Boehringer Ingelheim is preparing for multiple drug launches in the second half of 2025,

News

LEO Pharma has licensed a medicine for a rare form of psoriasis from Boehringer Ingelheim, plugging a gap in its near-term product portfolio.

News

Boehringer has started a phase 2 trial of an oral therapy that could help people with diabetic macular oedema avoid regular injections into the eye.